Columbia University Vagelos College of Physicians and Surgeons

Recor Medical Announces Positive Results from Six-Month Pooled Analysis of Data from the RADIANCE Global Clinical Trial Program at TCT 2023

Retrieved on: 
Thursday, October 26, 2023
Health, Clinical Trials, Cardiology, Medical Devices, BP, Surgeon, Blood pressure, TRIO, Hypertension, Physician, Columbia University, NewYork-Presbyterian Hospital, Columbia University Vagelos College of Physicians and Surgeons, Patient, Hospital, Pharmaceutical industry, Circulation, Medicine

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced positive results from a combined analysis of six-month follow-up data from the three RADIANCE global clinical studies evaluating the Paradise™ Ultrasound Renal Denervation (uRDN) system as a treatment for hypertension.

Key Points: 
  • Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced positive results from a combined analysis of six-month follow-up data from the three RADIANCE global clinical studies evaluating the Paradise™ Ultrasound Renal Denervation (uRDN) system as a treatment for hypertension.
  • Analysis demonstrated maintained blood pressure (BP) reduction following treatment with uRDN when compared to sham, with fewer antihypertensive treatments added in the treated group.
  • The RADIANCE Pooled Analysis includes data collected through six months follow-up from 506 patients randomized in the three studies from Recor’s RADIANCE Global Program: RADIANCE-HTN TRIO, which studied patients with resistant hypertension, and RADIANCE-HTN SOLO and RADIANCE II, which studied patients with mild-moderate hypertension.
  • The combined analysis demonstrated fewer medications were added in the uRDN group at 6 months compared to sham.

Acadia Healthcare Welcomes Dr. Patrice A. Harris, MD, MA as Independent Director

Retrieved on: 
Thursday, October 26, 2023
Mental Health, Other Health, Hospitals, Health, Managed Care, Grady EMS, MA, Digital health, Virginia University, West Virginia University, Health care, American Psychiatric Association, Committee, American Medical Association, APA, Patrice Harris, Entrepreneurship, Columbia University Vagelos College of Physicians and Surgeons, Morehouse School of Medicine, Multimedia, AMA, Legislation, Private practice, Behavioural sciences, Trustee, Growth, Physician, Substance abuse, Independent, Emory University School of Medicine, Acadia Healthcare, Outline of counseling, Public, African, California Community College Athletic Association, Mental health, Pharmaceutical industry, Nursing, Surgeon, MD, Psychiatry, Psychology, Medicine

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that Dr. Patrice A. Harris, MD, MA has been appointed to the Company’s Board of Directors effective October 26, 2023.

Key Points: 
  • Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that Dr. Patrice A. Harris, MD, MA has been appointed to the Company’s Board of Directors effective October 26, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20231026253607/en/
    Acadia Healthcare welcomes Dr. Patrice A. Harris, MD, MA as Independent Director (Photo: Business Wire)
    Dr. Harris is board-certified in psychiatry and has diverse experience as a private practicing physician, public health director and patient advocate.
  • Currently, Dr. Harris continues in private practice and is Co-Founder and Chief Executive Officer of eMed Digital Healthcare, a digital healthcare company she co-founded in 2020.
  • I am excited to be part of Acadia’s growth and the quality care it provides,” said Dr. Harris.

Alercell's Latest Intellectual Property In-License Bolsters Leukemia Diagnostic Test Advancements

Retrieved on: 
Wednesday, October 25, 2023
Leukemia, Patent, Therapy, Assistant, Oncology, Doctor of Philosophy, Columbia University Vagelos College of Physicians and Surgeons, Cell, TED, Physician, Chan, Columbia University, Classification, Patient, Diagnosis, Edward, Pharmaceutical industry, Surgeon, MD, Medicine

Under the license agreement, Alercell will spearhead the development of a novel diagnostic test for Leukemia which uses terminal erythroid differentiation (TED) as a clinically significant indicator for prognostic classification in patients with myeloid malignancies.

Key Points: 
  • Under the license agreement, Alercell will spearhead the development of a novel diagnostic test for Leukemia which uses terminal erythroid differentiation (TED) as a clinically significant indicator for prognostic classification in patients with myeloid malignancies.
  • Frederic Scheer, the Chief Executive Officer of Alercell, expressed immense enthusiasm regarding this patent license agreement, stating, "We are delighted to license this intellectual property from Columbia University.
  • At Alercell, our mantra is 'knowing before it is too late,' and licensing rights to the patent aligns seamlessly with our unwavering commitment."
  • Alercell's license agreement with Columbia University marks a significant stride for Alercell in the realm of cancer diagnostics, reinforcing the company's dedication to ushering in groundbreaking advancements in the field.

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Retrieved on: 
Thursday, October 5, 2023
ACT, Congress, ALS, Neuromuscular medicine, Columbia University Vagelos College of Physicians and Surgeons, MBA, Food, Doctor of Philosophy, Biomarker, Division, Research, Medicine, National Institute of Neurological Disorders and Stroke, FAAN, Master of Science, Neurology, NINDS, Safety, Columbia University, Survival, SALT, Disease, Surgeon, FDA, Collection, Clinical trial, DSM-IV codes, Microsoft Access, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bangladesh Technical Education Board, MHS, CNM, Physician, 21st Century Cures Act, EAP, Patient, NIH, Pharmaceutical industry, MD, Stroke

In addition to this new EAP, Clene will continue to conduct its currently ongoing ALS EAP programs that have enrolled more than 200 participants since 2019.

Key Points: 
  • In addition to this new EAP, Clene will continue to conduct its currently ongoing ALS EAP programs that have enrolled more than 200 participants since 2019.
  • The EAP grant is part of the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS).
  • This EAP will provide eligible people living with ALS to work with their clinician to access CNM-Au8.
  • These data can help provide confirmatory support for the existing trial data Clene has gathered in its clinical trials.”
    This study is supported by NIH grant U01NS136023.

Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Retrieved on: 
Thursday, October 5, 2023
Health, FDA, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Annual general meeting, Constipation, Columbia University Vagelos College of Physicians and Surgeons, Functional constipation, Division, Gastrointestinal disease, Drug development, Treatment, Diarrhea, Food and Drug Administration, Society, University, Ironwood Pharmaceuticals, Columbia University, AbbVie, Hospital, Defecation, Patient, Education, Head, Clinical trial, University of Connecticut School of Medicine, Medication, Bisacodyl, PDT, Physician, Research, Surgeon, Pharmaceutical industry, Birth control, Nursing, Ironwood, Pediatrics, Hepatology, Nutrition

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) Annual Meeting demonstrating that linaclotide decreased the use of rescue medications in children and adolescents ages 6-17 years-old with functional constipation.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) Annual Meeting demonstrating that linaclotide decreased the use of rescue medications in children and adolescents ages 6-17 years-old with functional constipation.
  • The analysis found that approximately half of the children enrolled in the trial relied on rescue medications at least once per week for symptom relief.
  • The symposium, which is not an official NASPGHAN event/function, will provide meeting attendees with an overview of pediatric functional constipation, presentation/diagnosis and management.
  • The post-hoc analysis demonstrated that in pediatric patients with functional constipation, diarrhea occurred in 7.4 percent of the linaclotide-treated population and 1.5 percent of those receiving placebo.

Lyme & Other Tick-Borne Diseases: Research & Clinical Advances 2023

Retrieved on: 
Thursday, October 5, 2023
Lyme, AMA, Doctor of Philosophy, Chemotherapy, Faculty, POTS, Late, Lyme disease, COVID, CME, MD, New Lyme, B cell, LDA, Columbia University Vagelos College of Physicians and Surgeons, MBI, Mast cell, Syndrome, Physician, Surgeon, Notifiable disease, Pharmaceutical industry, Vaccine, Microbiology, Babesia

JACKSON, N.J., Oct. 5, 2023 /PRNewswire/ -- Lyme Disease Association Inc. (LDA) will hold its 22nd annual scientific conference, Lyme & Other Tick-Borne Diseases: Research & Clinical Advances 2023, virtually on October 13-14, 2023.

Key Points: 
  • JACKSON, N.J., Oct. 5, 2023 /PRNewswire/ -- Lyme Disease Association Inc. (LDA) will hold its 22nd annual scientific conference, Lyme & Other Tick-Borne Diseases: Research & Clinical Advances 2023, virtually on October 13-14, 2023.
  • LDA and Columbia Vagelos College of Physicians and Surgeons are joint providers of the CME conference designed for medical & health professionals & researchers but open to the general public.
  • Topics include Lyme & COVID, Cancer Drug May Help Lyme, Psychedelics, Long-Term Lyme Treatments, Lyme Treatment Trials, Pathogens in Post Mortem Tissue, Mast Cell activation, Alpha-gal, Diagnostics, Eye Screening for Lyme, POTS, and Babesia.
  • Columbia University Vagelos College of Physicians and Surgeons designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credits™.

Northwell Health’s Dr. Zenobia Brown Named to Modern Healthcare’s 2023 Top Innovators List

Retrieved on: 
Friday, September 22, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Modern Healthcare, Hospital, University Medical Center, Maternal health, Physician, Woman, Top, Multimedia, Black, Creativity, Organization, House Calls, Columbia University Vagelos College of Physicians and Surgeons, Patient, Palliative care, Surgeon, Artificial intelligence, Navigation, Mortality, Columbia University College of Dental Medicine, MPH, Credit, RPM, Mother, Disease, Management, Medical device, Northwell Health, MD

Northwell Health’s Zenobia Brown, MD, MPH, senior vice president, associate chief medical officer and executive director of Northwell Health Solutions , is recognized by Modern Healthcare as one of the Top Innovators 2023.

Key Points: 
  • Northwell Health’s Zenobia Brown, MD, MPH, senior vice president, associate chief medical officer and executive director of Northwell Health Solutions , is recognized by Modern Healthcare as one of the Top Innovators 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230922768017/en/
    Northwell’s Dr. Zenobia Brown has been recognized as one of Modern Healthcare’s Top Innovators 2023.
  • (Credit: Northwell Health)
    “It’s an honor to be named a Modern Healthcare Top Innovator among so many other leaders and disruptors in this space,” said Dr. Brown.
  • Dr. Brown is an advocate and outspoken on the need to address social determinants of health to better care for all communities.

VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Retrieved on: 
Thursday, September 7, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Herbert Irving Comprehensive Cancer Center, GBM, Cytomegalovirus, Clinical trial, Neuro-Oncology (journal), Physician, Survival, Hope, Toxicity, VBI, Associate, Glioblastoma, Combination therapy, HIV disease progression rates, Patient, Standard of care, Columbia University Vagelos College of Physicians and Surgeons, CMV, Decompression (diving), Mortality, Neoplasm, Neuro, MOS, NCI, Vaccine, Safety, Disease, Pharmaceutical industry, Surgeon

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the first patients have been dosed in the randomized, controlled Phase 2b study of VBI’s cancer vaccine immunotherapeutic candidate, VBI-1901, in patients with first recurrent glioblastoma (rGBM).

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the first patients have been dosed in the randomized, controlled Phase 2b study of VBI’s cancer vaccine immunotherapeutic candidate, VBI-1901, in patients with first recurrent glioblastoma (rGBM).
  • The study will assess the safety, tolerability, tumor response rates, and survival following treatment with VBI-1901, as a monotherapy, at 10 leading neuro-oncology centers across the United States.
  • As we work to offer new hope to the patients, family members, and caretakers who are battling this devastating and historically treatment-resistant brain tumor, we are excited to kick-off this next phase of development for VBI-1901.”
    In the Phase 1/2a study of VBI-1901 in the rGBM setting, extensive biomarker panels suggested normal baseline CD4+/CD8+ T-cell ratios, which is a measure of immunological fitness, along with boosting of cytomegalovirus (CMV) gB specific antibody responses were correlated with tumor and clinical responses.
  • These learnings have been incorporated into patient enrollment eligibility criteria for the Phase 2b study to help identify patient populations that may be more likely to respond to treatment with VBI-1901.

Hip Hop and Environmental Nonprofits Drop Beats for Asthma Awareness and Health Education

Retrieved on: 
Wednesday, August 30, 2023
Medicine, Music, Asthma, Partnership, Education, Community, Friends, Culture, Physician, Research, Element, Black, MS, Science, Columbia University Vagelos College of Physicians and Surgeons, Head, RN, Health, MPH, Health literacy, Family, Empowerment, Community health, Risk management, Nursing, Pharmaceutical industry, MD, Surgeon, EMPOWER

WASHINGTON, Aug. 30, 2023 /PRNewswire-PRWeb/ -- Using music to teach and inspire healthy behaviors, Hip Hop Public Health (HHPH), the globally award-winning nonprofit co-founded by renowned neurologist, Dr. Olajide Williams and hip hop icon Doug E. Fresh, has joined forces with the National Environmental Education Foundation (NEEF) to create a dynamic educational multimedia collection called EMPOWER. Comprised of eight original songs and animated videos, EMPOWER aims to inspire young people with asthma to take charge of their health with evidence-based, self-management skills.

Key Points: 
  • EMPOWER, a dynamic collaboration between Hip Hop Public Health and the National Environmental Education Foundation (NEEF), harnesses the talents of emerging musical artists and multi-platinum producer and composer Q.
  • Worthy, to create original songs and animated videos to inspire young people with asthma to take charge of their health.
  • Comprised of eight original songs and animated videos, EMPOWER aims to inspire young people with asthma to take charge of their health with evidence-based, self-management skills.
  • The EMPOWER songs, videos, and accompanying printable educational assets are accessible for free through Hip Hop Public Health's Learning Studio .

RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS

Retrieved on: 
Monday, August 28, 2023
Morgan Stanley, Maimonides Medical Center, IPO, IOMA, ALZA, Pediatrics, Biochemistry, Physician, Columbia University Vagelos College of Physicians and Surgeons, OTCQB, Brandeis University, Pediatric Research, Research, RNA, Associate, Professor, Columbia, Supergene, Surgeon, Steroid, Pharmaceutical industry, Medical device, SUNY

PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS™.

Key Points: 
  • PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS™.
  • As RetinalGeniX DNA-GPS™ seeks to evolve into a diagnostic and therapeutic company, it plans to use pharmacogenetic mapping and high-resolution imaging RetinalGeniX DNA-GPS to validate and guide the development of novel methods and therapeutic products.
  • “Dr.
  • We welcome the expertise that Fred brings to RetinalGeniX DNA-GPS to assist in the development of this new technology in healthcare,” said Dr. Larry Perich, Director of the DNA/GPS program at RetinalGeniX.